Sign in Subscribe

Archive

A collection of 715 issues

Latest

Review examines liquid biopsy potential and limitations for CRC screening

Skip to content The CRC Digest Review examines liquid biopsy potential and limitations for CRC screening Analysis notes promise of circulating tumor DNA and cells for detection but highlights limited sensitivity for advanced adenomas and lack of randomized trial evidence for mortality reduction. (Intestinal Research) This content is informational only

New blood test achieves 60% sensitivity for early-stage cancers

Skip to content The CRC Digest New blood test achieves 60% sensitivity for early-stage cancers Caris Detect combines whole genome sequencing and AI; ACHIEVE 1 study showed 60.3% sensitivity for stage I-II cancers including colorectal. (Fierce Biotech) This content is informational only and does not constitute medical advice. Always

BREAKWATER explores molecular markers in BRAF V600E disease

Skip to content The CRC Digest BREAKWATER explores molecular markers in BRAF V600E disease Phase III trial data from ESMO GI examines correlates of response to encorafenib plus cetuximab and chemo. (Oncodaily) This content is informational only and does not constitute medical advice. Always consult your oncologist or care team.

Early-onset CRC shows distinct prognostic factors compared to late-onset disease

Skip to content The CRC Digest Early-onset CRC shows distinct prognostic factors compared to late-onset disease Retrospective study of 1,148 patients (247 under age 50) used machine learning to identify age-specific prognostic factors for overall survival. (PeerJ) This content is informational only and does not constitute medical advice. Always

CRC Research Finding

Skip to content The CRC Digest Dihydroartemisinin targets KRASG12D to overcome immunotherapy resistance Anti-malaria drug selectively downregulates KRASG12D mutant protein and enhances regorafenib plus anti-PD-1 in preclinical liver metastasis models. (Cell Death & Disease) This content is informational only and does not constitute medical advice. Always consult your oncologist or

This Week in CRC Research — July 05, 2026

Weekly colorectal cancer research intelligence

Researchers question whether lymph node removal may impair immunotherapy response

Skip to content The CRC Digest ◇ RESEARCH Researchers question whether lymph node removal may impair immunotherapy response — Colorectal Disease A hypothesis-generating review examines whether routine lymphadenectomy (removal of ≥12 lymph nodes, a well-recognized quality indicator in colorectal cancer surgery) may theoretically impair systemic immune surveillance and immune checkpoint inhibitor (ICI)

CT radiomics identifies imaging biomarkers in RAS-mutant metastatic colorectal cancer

Skip to content The CRC Digest ◇ RESEARCH CT radiomics identifies imaging biomarkers in RAS-mutant metastatic colorectal cancer — European Journal of Radiology Researchers established a co-clinical computed tomography (CT) radiomics pipeline for identifying candidate imaging biomarkers in RAS-mutant metastatic colorectal cancer. Orthotopic KRAS-mutant xenograft models (LOVO-Luc2 and SW480-Luc2, N=52 each)

Irisin enhances 5-fluorouracil effectiveness in colon cancer cells

Skip to content The CRC Digest ◇ RESEARCH Irisin enhances 5-fluorouracil effectiveness in colon cancer cells — International Journal of Applied and Basic Medical Research Human HT-29 CRC cells were treated for 12 hours with irisin (2, 20, and 200 ng/mL) alone or combined with 5-FU (50 μM). Cell cycle progression

Scientists identify metabolic pathway driving cetuximab resistance

Skip to content The CRC Digest ◇ RESEARCH Scientists identify metabolic pathway driving cetuximab resistance — Cell Death & Disease Researchers discovered that glutamate dehydrogenase 1 (GDH1) accumulation drives cetuximab resistance in metastatic colorectal cancer. When cetuximab blocks EGFR, it prevents phosphorylation of GDH1, leading to its accumulation and increased production of